MariMed (OTCQB: MRMD) CEO adds 40,000 shares to direct stake

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share. Following this trade, he owns 21,247,986 shares directly. A separate 6,684,640 shares are held by the Jon Levine Family Trust for his spouse and children, which he disclaims as beneficially owned.

Insider Trade Summary

Net Buyer: 40,000 shares ($3,000)

Net Buy 2 txns

Insider Levine Jon R

Role President and CEO

Bought 40,000 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common stock	40,000	$0.075	$3K
holding	Common stock	--	--	--

Holdings After Transaction: Common stock — 21,247,986 shares (Direct, null); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)

Footnotes (1)

1. [object Object]

Key Figures

Open-market purchase: 40,000 shares Purchase price: $0.075/share Direct holdings after trade: 21,247,986 shares +1 more

4 metrics

Open-market purchase 40,000 shares Common stock bought at $0.075 per share

Purchase price $0.075/share Price paid in open-market transaction

Direct holdings after trade 21,247,986 shares Common stock directly owned after May 20, 2026 transaction

Shares in family trust 6,684,640 shares Held by the Jon Levine Family Trust; beneficial ownership disclaimed

Key Terms

open-market purchase, beneficial ownership, Section 16, trust, +1 more

5 terms

open-market purchase financial

"reported an open-market purchase of 40,000 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"beneficial owner of these securities for purposes of Section 16"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

trust financial

"These shares are held in trust for the benefit of the Reporting Person's spouse and children"

indirect ownership financial

"nature_of_ownership: By the Jon Levine Family Trust"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Jon R

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD, MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	05/20/2026		P		40,000	A	$0.075	21,247,986	D
Common stock								6,684,640	I	By the Jon Levine Family Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Jon R. Levine	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MariMed (MRMD) CEO Jon R. Levine report?

Jon R. Levine reported buying 40,000 MariMed common shares in an open-market transaction at $0.075 per share. After this purchase, his direct holdings increased to 21,247,986 shares, according to the Form 4 insider ownership report.

At what price did MariMed CEO Jon R. Levine buy additional MRMD shares?

He purchased 40,000 MariMed common shares at $0.075 per share in an open-market transaction. This price and share amount are disclosed in the Form 4, which details his latest change in direct ownership of the company’s stock.

How many MariMed shares does Jon R. Levine now hold directly after this Form 4?

Following the reported open-market purchase, Jon R. Levine directly holds 21,247,986 shares of MariMed common stock. This total reflects his position after acquiring 40,000 additional shares, as disclosed in the Form 4 filing with the SEC.

What is the role of the Jon Levine Family Trust in MariMed (MRMD) share ownership?

The Jon Levine Family Trust holds 6,684,640 MariMed common shares for the benefit of his spouse and children. The filing states Levine disclaims beneficial ownership of these trust-held shares, meaning they are reported but not counted as his personal economic interest.

Does Jon R. Levine’s Form 4 include any stock option or derivative transactions?

No derivative or option exercises are reported in this Form 4. The filing shows a single open-market purchase of 40,000 common shares, plus a separate line reflecting 6,684,640 shares held indirectly by the Jon Levine Family Trust with disclaimed beneficial ownership.